Sorin, a medical device company, has received CE Mark approval for its Intensia family of implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy (CRT-D) devices.
The Intensia family includes single-chamber Intensia VR, dual-chamber Intensia DR and Intensia SonR CRT-D devices. All of these Intensia devices feature a DF-4 high voltage connector.
The DF-4 high voltage connector reduces the number of connections between the implanted device and the defibrillation (high voltage) lead from two to three to only one.
The new devices incorporates the company’s proprietary algorithms which improve cardiac resynchronization therapy (CRT) response, promote physiological pacing and minimize inappropriate shocks.
The INTENSIA SonR CRT-D with automatic CRT optimization allows heart failure patients to benefit from efficient resynchronization at rest and exercise.
The SonR algorithm, which showed 23% improvement in CRT response, automatically adjusts the resynchronization settings, eliminating the time-consuming manual process.
SonR devices feature a SonRtip lead with hemodynamic sensor that measures the contractility of the left ventricle.
The SafeR pacing mode of Intensia DR nearly eliminates unnecessary ventricular pacing and the PARAD+ arrhythmia discrimination algorithm minimizes the number of inappropriate shocks.
The radio-frequency enabled Intensia devices allow convenient and efficient follow-up with the SMARTVIEW remote monitoring solution.
Sorin CRM business unit president Stefano Di Lullo said: "We are committed to continuing technological improvements across our entire line of cardiac rhythm devices to improve patients’ lives and enable physicians to provide even better patient care in the changing healthcare landscape."
Image: Sorin launches INTENSIA family Of ICD and CRT-D devices. Photo: Courtesy of Sorin